Starpharma Holdings Past Earnings Performance
Past criteria checks 0/6
Starpharma Holdings's earnings have been declining at an average annual rate of -0.8%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 7% per year.
Key information
-0.8%
Earnings growth rate
1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 7.0% |
| Return on equity | -24.4% |
| Net Margin | -79.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?
Dec 18
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation
Nov 22Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money
Mar 21We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely
Jan 26We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
Jun 21Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?
May 16Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation
Mar 02Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?
Feb 10
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future
Jan 20Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?
Dec 28How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?
Dec 07Revenue & Expenses BreakdownBeta
How Starpharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 11 | -8 | 7 | 0 |
| 30 Sep 23 | 7 | -12 | 7 | 0 |
| 30 Jun 23 | 4 | -16 | 8 | 0 |
| 31 Mar 23 | 5 | -16 | 8 | 0 |
| 31 Dec 22 | 5 | -16 | 7 | 0 |
| 30 Sep 22 | 5 | -16 | 7 | 0 |
| 30 Jun 22 | 5 | -16 | 7 | 0 |
| 31 Mar 22 | 5 | -17 | 7 | 0 |
| 31 Dec 21 | 4 | -18 | 7 | 0 |
| 30 Sep 21 | 4 | -19 | 7 | 0 |
| 30 Jun 21 | 3 | -20 | 7 | 0 |
| 31 Mar 21 | 3 | -19 | 7 | 0 |
| 31 Dec 20 | 3 | -19 | 6 | 0 |
| 30 Sep 20 | 5 | -17 | 6 | 0 |
| 30 Jun 20 | 7 | -15 | 6 | 0 |
| 31 Mar 20 | 7 | -14 | 6 | 3 |
| 31 Dec 19 | 8 | -13 | 7 | 5 |
| 30 Sep 19 | 5 | -14 | 7 | 8 |
| 30 Jun 19 | 3 | -14 | 6 | 10 |
| 31 Mar 19 | 4 | -13 | 6 | 10 |
| 31 Dec 18 | 4 | -11 | 6 | 10 |
| 30 Sep 18 | 5 | -11 | 5 | 10 |
| 30 Jun 18 | 5 | -10 | 5 | 11 |
| 31 Mar 18 | 5 | -12 | 5 | 12 |
| 31 Dec 17 | 4 | -13 | 5 | 13 |
| 30 Sep 17 | 4 | -14 | 4 | 14 |
| 30 Jun 17 | 4 | -15 | 4 | 15 |
| 31 Dec 16 | 1 | -20 | 4 | 17 |
| 30 Sep 16 | 3 | -20 | 4 | 19 |
| 30 Jun 16 | 5 | -21 | 4 | 21 |
| 31 Mar 16 | 5 | -22 | 5 | 21 |
| 31 Dec 15 | 5 | -20 | 4 | 21 |
| 30 Sep 15 | 3 | -20 | 4 | 19 |
| 30 Jun 15 | 2 | -19 | 4 | 16 |
| 31 Mar 15 | 1 | -18 | 5 | 15 |
| 31 Dec 14 | 1 | -18 | 5 | 14 |
| 30 Sep 14 | 1 | -16 | 5 | 12 |
| 30 Jun 14 | 1 | -15 | 5 | 11 |
| 31 Mar 14 | 2 | -12 | 4 | 9 |
| 31 Dec 13 | 2 | -9 | 4 | 7 |
| 30 Sep 13 | 2 | -7 | 4 | 5 |
| 30 Jun 13 | 2 | -5 | 4 | 4 |
Quality Earnings: SPL is currently unprofitable.
Growing Profit Margin: SPL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPL is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare SPL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: SPL has a negative Return on Equity (-24.37%), as it is currently unprofitable.